Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …

Advances in the field of boron chemistry have expanded the application of this element in
Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal …

There is an urgent need to develop new and safer antitubercular agents that possess a
novel mode of action. We synthesized and evaluated a novel series of 3-aminomethyl 4 …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

Aminoacyl-tRNA synthetases (ARSs) are universal enzymes that catalyze the attachment of
amino acids to the 3′ ends of their cognate tRNAs. The resulting aminoacylated tRNAs are …

Aminoacyl-tRNA synthetases (ARSs) play a vital role in protein synthesis by linking amino
acids to their cognate transfer RNAs (tRNAs). This typical function has been well recognized …

Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB
epidemic. Recent efforts have focused on the development of whole-cell screening assays …

Tuberculosis now ranks as the leading cause of death in the world due to a single infectious
agent. Current standard of care treatment can achieve very high cure rates for drug-sensitive …

Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium
tuberculosis (Mtb), has burdened vulnerable populations in modern day societies for …